Synonyms: HLA class I, HLA-A/B/C Clone No.:W6/32
Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. All human nucleated cell express MHC class I antigens associated with β2-microglobulin. MHC class I plays a central role in cell-mediated immune responses and tumor surveillance.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Molecular Weight | 150 kDa |
|---|---|
| Clone | W6/32 |
| Isotype | mouse IgG2a,κ |
| Application | Anti-human MHC Class I (HLA-A, HLA-B, HLA-C)-InVivo |
| Source | CHO |
| Purification | Protein G |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.0. Contains no stabilizers or preservatives |
| Murine Pathogen Screening Panel | all targets tested yielded Negative Results: Theiler’s Murine Encephalomyelitis Virus, Ectromelia (Mousepox) Virus, Hantavirus, Polyomavirus, Sendai Virus, Mycoplasma pulmonis, Pneumonia Virus of Mice, K Virus, Mouse Parvovirus, Mouse Hepatitis Virus, Mouse Norovirus, Mouse Minute Virus, Mouse Cytomegalovirus, Mouse Adenovirus, Lactate Dehydrogenase-Elevating Virus, Reovirus Panel, Lymphocytic Choriomeningitis Virus, Mouse Rotavirus. |
| Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06246149 | RECRUITING | Drug: Tebentafusp | Uveal Melanoma | European Organisation for Research and Treatment of Cancer - EORTC | 2024-11-11 | PHASE3 |
| NCT06942442 | RECRUITING | Drug: Physician's Choice|Drug: Tebentafusp | HLA-A*0201 Positive Cells Present; Clear Cell Sarcoma (CCS) | Sarcoma Alliance for Research through Collaboration | 2025-10-22 | PHASE2 |
| NCT07645469 | RECRUITING | Drug: Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 T | Acute Myeloid Leukemia | Fred Hutchinson Cancer Center | 2026-09-01 | PHASE1 |
| NCT07145450 | RECRUITING | PDAC | Anocca AB | 2025-07-03 | PHASE1; PHASE2 | |
| NCT07583316 | NOT_YET_RECRUITING | Drug: CRPA1A2 | Lung Cancer (Locally Advanced or Metastatic); Esophagus Cancer; Head and Neck Cancer; Hepatocellular Carcinoma (HCC) | Corregene Biotechnology Co., Ltd | 2026-05-29 | PHASE1 |
| NCT05751798 | RECRUITING | Drug: Part A: OSE-279 100mg|Drug: Part A: OSE-279 300mg|Drug | Solid Advanced Tumor; Lymphoma; NSCLC (Non-small Cell Lung Cancer) | OSE Immunotherapeutics | 2022-12-20 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-30)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.